Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine

Samarkanova, Dinara; Cox, S.T.; Hernandez, Diana; Rodríguez, Laura; Casaroli-Marano, Ricardo P.; Madrigal, Alejandro; Querol, Sergio

doi:10.3389/fimmu.2020.00942

Cited by 16 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also contains a greater amount of growth factors and cytokines, in particular Interleukine-10 (IL-10) which has been correlated with the decrease in VAS pain score [ 10 ]. Thanks to these advantages, C-PRP has so far been used successfully in various fields of medicine [ 32 ]: in ophthalmology for the treatment of corneal diseases and severe dry eye problems, and in the dermatological field for the healing of wounds and skin lesions. Nevertheless, evidence on the application of C-PRP in orthopedic diseases, including hip OA, is still limited, despite the growing interest in the use of homologous sources of PRP.…”

Section: Discussionmentioning

confidence: 99%

“…In particular, it has been emphasized that the best results in PRP treatments can be obtained in young patients, with low BMI and with less cartilage damage [ 45 ]. Previous studies have already showed worse results in patients with greater OA levels [ 10 , 32 ]. Similarly, the analysis on influencing factors in this study showed how the OA grade, quantified with the classification of Tonnis, was a determining aspect.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis

Mazzotta

Pennello

Stagni

et al. 2022

JCM

View full text Add to dashboard Cite

Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the treatment of patients with hip osteoarthritis (OA). This study investigated the results of 100 patients with hip OA treated with three weekly ultrasound-guided injections of either C-PRP or A-PRP. Clinical evaluations were performed before the treatment and after two, six, and twelve months with the HHS, WOMAC, and VAS scores. No major adverse events were recorded. Overall, the improvement was limited with both treatments. Significant improvements in VAS (p = 0.031) and HHS (p = 0.011) were documented at two months for C-PRP. Patients with a low OA grade (Tonnis 1-2) showed a significantly higher HHS improvement with C-PRP than A-PRP at twelve months (p = 0.049). C-PRP injections are safe but offered only a short-term clinical improvement. The comparative analysis did not demonstrate benefits compared with A-PRP in the overall population, but the results are influenced by OA severity, with C-PRP showing more benefits when advanced OA cases were excluded. Further studies are needed to confirm the most suitable indications and potential of this biological injective approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis

Mazzotta

Pennello

Stagni

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…A detailed discussion of the in vitro uses and in vivo therapeutic applications of these novel CB components is outside the scope of this article. The interested reader can find the encouraging, preliminary evidences so far reported in several reviews ( Petrini, 2012 ; Querol and Samarkanova, 2019 ; Rebulla et al, 2019 ; Samarkanova et al, 2020a ) and laboratory studies ( Parazzi et al, 2010 ; Cox et al, 2015 ; Parazzi et al, 2015 ; Ferri et al, 2016 ; Longo et al, 2016 ; Rebulla et al, 2016 ; Shirzad et al, 2017 ; Stokhuijzen et al, 2017 ; Christou et al, 2018 ; Cox et al, 2018 ; Valentini et al, 2019 ; Samarkanova et al, 2020b ; Rallapalli et al, 2021 ). A selection of published investigations on the clinical use of CB platelets, plasma and red blood cells in wound healing, ophthalmology, neonatal and pediatric transfusion is reported in Table 1 .…”

Section: Introductionmentioning

confidence: 90%

“…To increase this number to the desired target, the 6 CB programs have collected a median of 7142 (2365-13081) units per year during 2016–2020 (note that the advent of the COVID-19 pandemic and the associated restrictions have substantially reduced collection activities during 2020). From all collected units, only 13% ( Petrini, 2012 ; Cox et al, 2015 ; Cox et al, 2018 ; Querol and Samarkanova, 2019 ; Rebulla et al, 2019 ; Samarkanova et al, 2020a ; Samarkanova et al, 2020b ) have finally been processed for transplantation.…”

Section: Introductionmentioning

confidence: 99%

Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain

Rebulla

Querol

Pupella³

et al. 2022

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

Most public cord blood banking programs are currently facing financial difficulties due to a progressive decline in the number of cord blood transplants performed worldwide and to a high discard rate of the donated units caused by progressively increasing thresholds of the stem cell dose required to perform safe and effective hemopoietic cord blood transplants. Recycling a proportion of unused cord blood units to prepare novel cord blood components obtained with minimal manipulation (platelets, plasma, red blood cells) and to develop more technologically complex products regulated in the US as Cellular and Gene Therapy Products and in Europe as Advanced Therapy Medicinal Products [e.g. virus-specific T cells (VST), natural killer (NK) cells, induced pluripotent stem cells (iPSCs) is a promising strategy to increase the therapeutic value and reduce the financial deficits of public cord blood banking. Based on encouraging preliminary evidences reported in the literature, additional laboratory studies, large multicenter clinical trials and international regulatory harmonization are necessary to achieve these important goals. This article describes organizational, methodological and regulatory advancements developed in Italy and Spain to promote the clinical use of cord blood platelets, plasma and red blood cells.

show abstract

“…It is known that the interplay between PDGF, FGF, TGF, and VEGF can promote the proliferation of cells and angiogenesis, resulting in advanced regeneration of the damaged tissue [ 20 , 21 , 22 ]. Currently, CB derivatives, such as the platelet rich plasma (PRP) and PL, have been applied with great success in several approaches involving skin lesions, occurring due to infection of Epidermolysis bullosa and also in patients suffering from diabetic ulcers [ 23 , 24 , 25 , 26 , 27 , 28 ]. Additionally, it has been reported that the CB-PPP contains a significant amount of growth factors, which may also exert wound healing properties [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Regenerative Potential of Platelet-Lysate and Platelet-Poor Plasma Derived from the Cord Blood Units in Corneal Wound Healing Applications: An In Vitro Comparative Study on Corneal Epithelial Cells

Mallis

Michalopoulos

Sarri

et al. 2022

CIMB

View full text Add to dashboard Cite

Background: Cord blood platelet lysate (CB-PL) and cord blood platelet poor plasma (CB-PPP) have been applied with success in wound healing applications. Pathologies such as Sjogrens’s Syndrome (SS) and chronic graft versus host disease (cGVHD) can lead to severe ophthalmology issues. The application of CB-PL and CB-PPP may be strongly considered for damaged cornea healing. This study aimed to the evaluation of the beneficial properties of CB-PL and CB-PPP in corneal wound healing applications. Methods: Initially, the CB-PL and CB-PPP were produced from donated cord blood units (CBUs), followed by biochemical analysis. Corneal epithelial cells (CECs) were isolated from wistar rats and then cultured with medium containing 20% v/v either of CB-PL or CB-PPP. To define the impact of CB-PL and CB-PPP, biochemical, morphological analysis, scratch-wound assays, and immunoassays in CECs were performed. Results: CB-PL and CB-PPP were characterized by good biochemical parameters, regarding their quality characteristics and biomolecule content. CECs’ morphological features did not change after their cultivation with CB-PL or CB-PPP. A scratch wound assay and molecular analysis of CECs expanded with CB-PL indicated higher migratory capacity compared to those cultured with CB-PPP. Conclusion: CB-PL and CB-PPP exhibited good properties with respect to cell migration and proliferation, and could be considered an alternative source for eye drop production, to possibly be used in cornea wound healing applications.

show abstract

Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine

Cited by 16 publications

References 43 publications

Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis

Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis

Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain

Evaluation of the Regenerative Potential of Platelet-Lysate and Platelet-Poor Plasma Derived from the Cord Blood Units in Corneal Wound Healing Applications: An In Vitro Comparative Study on Corneal Epithelial Cells

Contact Info

Product

Resources

About